Elevated GFAP levels were detected; therefore, GFAP levels may serve as an additional biomarker for major depression in the future, but further investigations, including multimodal longitudinal studies, are needed to clarify the exact role and reliability of intrathecal GFAP alterations in depression. This evidence concerns the gene GFAP and depressive disorder.